Inositol(s) in thyroid function, growth and autoimmunity

被引:33
作者
Benvenga, Salvatore [1 ,2 ,3 ]
Antonelli, Alessandro [4 ]
机构
[1] Univ Messina, Sch Med, Dept Clin & Expt Med, Via Consolare Valeria 1, I-98125 Messina, Italy
[2] Univ Messina, Sch Med, Master Program Childhood Adolescence andWomens, Via Consolare Valeria 1, I-98125 Messina, Italy
[3] Univ Hosp, Interdept Program Mol & Clin Endocrinol & Womens, Padiglione H,4 piano,Policlinico G. Martino, I-98125 Messina, Italy
[4] Univ Pisa, Dept Clin & Expt Med, I-56126 Pisa, Italy
关键词
Myo-inositol; Phosphatidylinositol; TSH; TSHR; Insulin; IGF-1R; POLYCYSTIC-OVARY-SYNDROME; ENDOCRINE DISRUPTING CHEMICALS; METABOLIC SYNDROME; INSULIN-RESISTANCE; SUBCLINICAL HYPOTHYROIDISM; STIMULATING HORMONE; HIGH PREVALENCE; RECEPTOR; MYOINOSITOL; PHOSPHATES;
D O I
10.1007/s11154-016-9370-3
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Myo-inositol and phosphatidylinositol(s) play a pivotal function in many metabolic pathways that, if impaired, impact unfavorably on human health. This review analyzes several experimental and clinical investigations regarding the involvement of this class of molecules in physiological and pathological situations, with a major focus on thyroid. Central issues are the relationship between phosphatidylinositol and thyrotropin (TSH) signaling on one hand, and phosphatydylinositol and autoimmunity on the other hand. Other issues are the consequences of malfunction of some receptors, such as those ones for TSH (TSHR), insulin (IR) and insulin-like growth factor-1 (IGF-1R), or the connection between serum TSH concentrations and insulin resistance. Also covered are insulin resistance, metabolic syndrome and their allied disorders (diabetes, polycystic ovary syndrome [PCOS]), autoimmunity and certain malignancies, with their reciprocal links. Myoinositol has promising therapeutic potential. Appreciation of the inositol pathways involved in certain disorders, as mentioned in this review, may stimulate researchers to envisage additional therapeutic applications.
引用
收藏
页码:471 / 484
页数:14
相关论文
共 95 条
[1]
Subclinical hypothyroidism is associated with early insulin resistance in Kuwaiti women [J].
Al Sayed, Ahmed ;
Al Ali, Nadia ;
Bo Abbas, Yosuf ;
Alfadhli, Eid .
ENDOCRINE JOURNAL, 2006, 53 (05) :653-657
[2]
Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study [J].
Antonelli, A. ;
Fallahi, P. ;
Ferrari, S. M. ;
Pupilli, C. ;
d'Annunzio, G. ;
Lorini, R. ;
Vanelli, M. ;
Ferrannini, E. .
DIABETIC MEDICINE, 2008, 25 (11) :1349-1353
[3]
α-Chemokine CXCL10 and β-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis [J].
Antonelli, Alessandro ;
Ferri, Clodoveo ;
Fallahi, Poupak ;
Ferrari, Silvia Martina ;
Frascerra, Silvia ;
Carpi, Angelo ;
Nicolini, Andrea ;
Ferrannini, Ele .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2008, 57 (09) :1270-1277
[4]
Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis [J].
Antonelli, Alessandro ;
Ferri, Clodoveo ;
Fallahi, Poupak ;
Cazzato, Massimiliano ;
Ferrari, Silvia Martina ;
Sebastiani, Marco ;
Ferrannini, Ele .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 156 (04) :431-437
[5]
Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases [J].
Antonelli, Alessandro ;
Ferrari, Silvia Martina ;
Giuggioli, Dilia ;
Ferrannini, Ele ;
Ferri, Clodoveo ;
Fallahi, Poupak .
AUTOIMMUNITY REVIEWS, 2014, 13 (03) :272-280
[6]
Balazs Csaba, 2008, Orvosi Hetilap, V149, P1227, DOI 10.1556/OH.2008.28408
[7]
Insulin receptor and cancer [J].
Belfiore, Antonino ;
Malaguarnera, Roberta .
ENDOCRINE-RELATED CANCER, 2011, 18 (04) :R125-R147
[8]
Ben-Shmuel S, 2016, HANDB EXP PHARMACOL, V233, P355, DOI 10.1007/164_2015_12
[9]
Update on thyroid cancer [J].
Benvenga, S. .
HORMONE AND METABOLIC RESEARCH, 2008, 40 (05) :323-328
[10]
Serum Thyroid Hormone Autoantibodies in Type 1 Diabetes Mellitus [J].
Benvenga, Salvatore ;
Pintaudi, Basilio ;
Vita, Roberto ;
Di Vieste, Giacoma ;
Di Benedetto, Antonino .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (05) :1870-1878